Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H15N3O4 |
| Molecular Weight | 313.308 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCN1C(=O)C2=CC=CC3=C2C(=CC(=C3)[N+]([O-])=O)C1=O
InChI
InChIKey=XXVLKDRPHSFIIB-UHFFFAOYSA-N
InChI=1S/C16H15N3O4/c1-17(2)6-7-18-15(20)12-5-3-4-10-8-11(19(22)23)9-13(14(10)12)16(18)21/h3-5,8-9H,6-7H2,1-2H3
| Molecular Formula | C16H15N3O4 |
| Molecular Weight | 313.308 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Mitonafide is a nitro-containing antitumor drug. Mitonafide participated in clinical trials phase II in colorectal cancer patients, however, the results have shown that the drug was not active and induced severe myelotoxicity. Besides, the drug was involved in phase II for the patients with non-small cell lung cancer (NSCLC), where it was not active in spite of the safe administration. Information about the current development of this drug is not available.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8913845
All but one received a 120-hour (5-day) continuous infusion of Mitonafide at a starting dose of 200 mg/m2/day every 3 weeks
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:16:23 GMT 2025
by
admin
on
Wed Apr 02 09:16:23 GMT 2025
|
| Record UNII |
06Q0V17SI9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C582
Created by
admin on Wed Apr 02 09:16:23 GMT 2025 , Edited by admin on Wed Apr 02 09:16:23 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID90203321
Created by
admin on Wed Apr 02 09:16:23 GMT 2025 , Edited by admin on Wed Apr 02 09:16:23 GMT 2025
|
PRIMARY | |||
|
100000080879
Created by
admin on Wed Apr 02 09:16:23 GMT 2025 , Edited by admin on Wed Apr 02 09:16:23 GMT 2025
|
PRIMARY | |||
|
C019215
Created by
admin on Wed Apr 02 09:16:23 GMT 2025 , Edited by admin on Wed Apr 02 09:16:23 GMT 2025
|
PRIMARY | |||
|
06Q0V17SI9
Created by
admin on Wed Apr 02 09:16:23 GMT 2025 , Edited by admin on Wed Apr 02 09:16:23 GMT 2025
|
PRIMARY | |||
|
327044
Created by
admin on Wed Apr 02 09:16:23 GMT 2025 , Edited by admin on Wed Apr 02 09:16:23 GMT 2025
|
PRIMARY | |||
|
CHEMBL43482
Created by
admin on Wed Apr 02 09:16:23 GMT 2025 , Edited by admin on Wed Apr 02 09:16:23 GMT 2025
|
PRIMARY | |||
|
4574
Created by
admin on Wed Apr 02 09:16:23 GMT 2025 , Edited by admin on Wed Apr 02 09:16:23 GMT 2025
|
PRIMARY | |||
|
SUB09007MIG
Created by
admin on Wed Apr 02 09:16:23 GMT 2025 , Edited by admin on Wed Apr 02 09:16:23 GMT 2025
|
PRIMARY | |||
|
C66165
Created by
admin on Wed Apr 02 09:16:23 GMT 2025 , Edited by admin on Wed Apr 02 09:16:23 GMT 2025
|
PRIMARY | |||
|
300288
Created by
admin on Wed Apr 02 09:16:23 GMT 2025 , Edited by admin on Wed Apr 02 09:16:23 GMT 2025
|
PRIMARY | |||
|
54824-17-8
Created by
admin on Wed Apr 02 09:16:23 GMT 2025 , Edited by admin on Wed Apr 02 09:16:23 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |